Legal Representation
Attorney
Anna King
USPTO Deadlines
Next Deadline
1844 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-11-26)
Due Date
November 26, 2030
Grace Period Ends
May 26, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
30 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Nov 26, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Nov 26, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Nov 5, 2024 | DP1B | I | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | Loading... |
| Nov 4, 2024 | D1BR | I | TEAS DELETE 1(B) BASIS RECEIVED | Loading... |
| Nov 4, 2024 | IUCN | S | NOTICE OF ALLOWANCE CANCELLED | Loading... |
| May 7, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Mar 12, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Mar 12, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Feb 21, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Feb 21, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Feb 2, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jan 30, 2024 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jan 30, 2024 | GNEA | O | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jan 30, 2024 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Jan 30, 2024 | GPRN | O | NOTIFICATION OF PRIORITY ACTION E-MAILED | Loading... |
| Jan 30, 2024 | GPRA | O | PRIORITY ACTION E-MAILED | Loading... |
| Jan 30, 2024 | CPRA | R | PRIORITY ACTION WRITTEN | Loading... |
| Dec 26, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Dec 26, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Dec 26, 2023 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Jul 31, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| May 18, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| May 18, 2023 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| May 18, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Apr 27, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Apr 27, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Apr 27, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Apr 25, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 16, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 28, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical and medical preparations for use in targeting genes and silencing or inhibiting gene expression; drug delivery agents that facilitate the delivery of pharmaceutical preparations targeting genes and silencing or inhibiting gene expression; drug delivery agents that facilitate the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs); drug delivery agents that facilitate the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs), all for targeting genes and silencing or inhibiting gene expression; RNAi-based medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; short interfering RNA-based (siRNA) medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; nucleic acid-based drugs (NABDs) for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation
Class 009
Downloadable and recorded computer software for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; downloadable and recorded artificial intelligence and machine learning software for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; electronic databases for use in the field of pharmaceuticals, medicines and drug discovery, namely, databases containing information relating to potential biological drug targets and gene-disease associations recorded on computer media; downloadable and recorded computer platform software for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; downloadable and recorded computer software platforms for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; downloadable and recorded computer software enabling the searching and retrieval of data relating to pharmaceuticals, medicines and drug discovery; downloadable and recorded software for the analysis of data relating to pharmaceuticals, medicines and drug discovery; downloadable and recorded search engine software for use in the field of pharmaceuticals, medicines and drug discovery; downloadable and recorded search engine software for the searching, retrieval, indexing and analysis of data relating to pharmaceuticals, medicines and drug discovery
Class 040
Custom manufacture of pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; custom manufacture of RNAi-based pharmaceuticals and medicines; custom manufacture of short interfering RNA (siRNA) medicines; custom manufacture of nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression; custom manufacture of pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid
Class 042
Scientific research and development in the field of targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to RNAi-based pharmaceuticals and medicines; scientific, pharmaceutical and medical research and development services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking gene expression, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and, pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; drug discovery services relating to RNAi-based pharmaceuticals and medicines; drug discovery services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; drug discovery services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; scientific and technical testing and data analysis in relation to pharmaceuticals and medicines; scientific and technical testing and data analysis in relation to RNAi-based medicines; scientific and technical testing and data analysis in relation to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific and technical testing and data analysis in relation to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design, development, creation and maintenance of computer platforms and computer software for use in the field of pharmaceuticals, medicines and drug discovery; design, development, creation and maintenance of computer platforms and computer software enabling the searching and retrieval of data relating to pharmaceuticals, medicines and drug discovery; design, development, creation and maintenance of computer platforms and computer software for the analysis of data relating to pharmaceuticals, medicines and drug discovery; design of and providing temporary use of online non-downloadable search engine software for use in the field of pharmaceuticals, medicines and drug discovery; design of and providing temporary use of online non-downloadable search engine software for the searching, retrieval, indexing and analysis of data relating to pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticals, medicines and drug discovery, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticals, medicines, and drug discovery, for generating RNAi-based medicines and pharmaceuticals, short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design and development of computer-simulated models for use in the field of pharmaceuticals, medicines and drug discovery; providing temporary use of online non-downloadable computer software for use in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; Software as a Service (SaaS) services featuring software using artificial intelligence and machine learning software and databases in the field of pharmaceuticals, medicines and drug discovery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; Software as a Service (SaaS) services featuring computer software platforms using artificial intelligence and machine learning for use in the field of pharmaceuticals, medicines and drug discovery, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating RNAi-based medicines and pharmaceuticals, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid
Classification
International Classes
005
009
040
042